PDCD1 and Autoimmunity: However, its inhibition may simultaneously diminish harmful myeloid-driven inflammation in autoimmune disorders, contrasting with PD-1 and CTLA-4 inhibitors, which frequently aggravate or induce autoimmune symptoms [70, 71].